Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Short term Debt: 2021-2024

  • ProQR Therapeutics N.V's Short term Debt was N/A to $4.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.9 million, marking a year-over-year change of. This contributed to the annual value of $4.9 million for FY2024, which is N/A change from last year.
  • Per ProQR Therapeutics N.V's latest filing, its Short term Debt stood at $4.9 million for Q4 2024, which was up 91.97% from $2.6 million recorded in Q4 2022.
  • ProQR Therapeutics N.V's 5-year Short term Debt high stood at $5.5 million for Q4 2021, and its period low was $2.6 million during Q4 2022.
  • For the 2-year period, ProQR Therapeutics N.V's Short term Debt averaged around $3.7 million, with its median value being $3.7 million (2022).
  • Data for ProQR Therapeutics N.V's Short term Debt shows a maximum YoY slumped of 53.27% (in 2022) over the last 5 years.
  • Over the past 3 years, ProQR Therapeutics N.V's Short term Debt (Quarterly) stood at $5.5 million in 2021, then crashed by 53.27% to $2.6 million in 2022, then reached $4.9 million in 2024.
  • Its last three reported values are $4.9 million in Q4 2024, $2.6 million for Q4 2022, and $5.5 million during Q4 2021.